ASX Announcements 2016

21.12.16 - Change in substantial holding

15.12.16 - Completion of Initial CMAX Transaction

22.11.16 - Mayne Pharma Announces U.S. Launch of IDT's Temozolomide

7.11.16 - Ceasing to be a substantial holder from AEF

2.11.16 - 1st generic proprietary product shipped to US, temozolomide

28.10.16 - IDT Divests CMAX Clinical Trial Business to I'rom Group

21.10.16 - Appendix 3B

18.10.16 - Results of Meeting

12.10.16 - Director Resignation

17.10.16 - Investor Presentation, AGM 17 October 2016

7.10.16 - Receives Export Award, Health and Biotechnology

20.9.16 - Change in substantial holder from AEF

21.9.16 - Cancellation of shares

21.9.16 - Appendix 3B

16.9.16 - Notice of Annual General Meeting/Proxy Form

9.9.16 - Change of Melbourne Registry Address Notification

6.9.16 - Awarded Future Industries Manufacturing Program Grant

25.8.16 - Appendix 4G

24.7.16 - Full Year Statutory Accounts

24.7.16 - Appendix 4E

3.7.16 - Appendix 3B

6.7.16 - Cleansing Notice

6.7.16 - Appendix 3B

1.7.16 - Becoming a substantial holder

30.6.16 - Completion of private placement

28.6.16 - Trading Halt

27.6.16 - Updated Investor Presentation

8.6.16 - Ceasing to be a substantial holder

2.5.16 - CMAX - Opening of new Clinical Trial Facility

4.4.16 - Updated Investor Presentation

13.4.16 - FDA Approval for Temozolomide

30.3.16 - Manufacturing partner appointed

9.3.16 - Thiotepa - Contract Extension and Revenues

19.2.16 - Half Yearly Report and Accounts

19.2.16 - Appendix 4D

15.2.16 - Ceasing to be a substantial holder

4.1.16 - Becoming a substantial holder